Correlation Between PepGen and Salarius Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both PepGen and Salarius Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining PepGen and Salarius Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between PepGen and Salarius Pharmaceuticals, you can compare the effects of market volatilities on PepGen and Salarius Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in PepGen with a short position of Salarius Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of PepGen and Salarius Pharmaceuticals.

Diversification Opportunities for PepGen and Salarius Pharmaceuticals

0.32
  Correlation Coefficient

Weak diversification

The 3 months correlation between PepGen and Salarius is 0.32. Overlapping area represents the amount of risk that can be diversified away by holding PepGen and Salarius Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Salarius Pharmaceuticals and PepGen is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on PepGen are associated (or correlated) with Salarius Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Salarius Pharmaceuticals has no effect on the direction of PepGen i.e., PepGen and Salarius Pharmaceuticals go up and down completely randomly.

Pair Corralation between PepGen and Salarius Pharmaceuticals

Given the investment horizon of 90 days PepGen is expected to under-perform the Salarius Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, PepGen is 1.04 times less risky than Salarius Pharmaceuticals. The stock trades about -0.18 of its potential returns per unit of risk. The Salarius Pharmaceuticals is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  144.00  in Salarius Pharmaceuticals on September 29, 2024 and sell it today you would earn a total of  23.00  from holding Salarius Pharmaceuticals or generate 15.97% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

PepGen  vs.  Salarius Pharmaceuticals

 Performance 
       Timeline  
PepGen 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days PepGen has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.
Salarius Pharmaceuticals 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Salarius Pharmaceuticals are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Salarius Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

PepGen and Salarius Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with PepGen and Salarius Pharmaceuticals

The main advantage of trading using opposite PepGen and Salarius Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if PepGen position performs unexpectedly, Salarius Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Salarius Pharmaceuticals will offset losses from the drop in Salarius Pharmaceuticals' long position.
The idea behind PepGen and Salarius Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum